CLASS II ONGOING Drug recall · Reported 31 Dec 2025 · FDA Enforcement Report
Merck Emend (aprepitant) for oral suspension, 125 mg recalled
Merck Sharp & Dohme is recalling Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, distributed nationwide in the US. The recall was initiated on 12 Dec 2025 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0241-2026
- FDA event ID
- 98113
- Recalling firm
- Merck Sharp & Dohme, Wilson, NC
- Brand
- Emend
- Manufacturer
- Merck Sharp & Dohme LLC
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 12 Dec 2025
- FDA classified
- 23 Dec 2025
- Reported
- 31 Dec 2025
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Particulate Matter
Timeline
| 12 Dec 2025 | Recall initiated by company | |
| 23 Dec 2025 | Classified by FDA | +11 days |
| 31 Dec 2025 | Published in enforcement report | +8 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Presence of particulate matter: potential presence of metal particulates in the product.
Product as listed by the FDA
Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland, NDC 0006-3066-03
Where it was distributed
Nationwide in the USA
Questions about this recall
Why was it recalled?
Presence of particulate matter: potential presence of metal particulates in the product.
Which lots are affected?
Lot #: Z014503, Exp 11/15/2027
Where was it sold?
Nationwide in the USA
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
1 other product · FDA event 98113| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| CLASS II | Noxafil Powdermix (posaconazole) recalled by Merck Sharp & DohmeNoxafil | Merck Sharp & Dohme | Particulate Matter | Nationwide |
More recalls from Merck Sharp & Dohme
All 5| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Noxafil Powdermix (posaconazole) recalled by Merck Sharp & DohmeNoxafil | Merck Sharp & Dohme | Particulate Matter | Nationwide |
| Drug | CLASS II | Janumet (sitagliptin and metformin HCl) tablets recalledJanumet | Merck Sharp & Dohme | Particulate Matter | Nationwide |
| Drug | CLASS I | Cubicin (daptomycin for injection), 500 mg per vial recalled | Merck Sharp & Dohme | Particulate Matter | Nationwide |
| Drug | CLASS II | Zerbaxa (ceftolozane and tazobactam) per vial for injection recalledZerbaxa | Merck Sharp & Dohme | Sterility | Nationwide |
Other Aprepitant recalls
All 3| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Aprepitant Capsule, USP, 40 mg per unit dose package recalledAprepitant | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS III | Aprepitant Capsules, USP 40 mg Unit recalled by Glenmark Pharmaceuticals | Glenmark Pharmaceuticals Inc., USA | Packaging Defects | Nationwide |